Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Head and neck cancer, excluding thyroid

3044 - An Open-label, Multicohort, Phase 1/2 Study in Patients With Virus-Associated Cancers (CheckMate 358): Safety and Efficacy of Neoadjuvant Nivolumab in Squamous Cell Carcinoma of the Head and Neck (SCCHN)


09 Sep 2017


Head and neck cancer, excluding thyroid


Head and Neck Cancers


Robert Ferris


Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440


R.L. Ferris1, A. Gonçalves2, S.S. Baxi3, U.M. Martens4, H. Gauthier5, M. Langenberg6, W.C. Spanos7, R.S. Leidner8, H. Kang9, J. Russell10, S. Chiosea11, I. Soumaoro12, S. Rao13, Z..A. Cao12, S. Topalian14

Author affiliations

  • 1 Department Of Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, 15232-1863 - Pittsburgh/US
  • 2 Department Of Medical Oncology, Institut Paoli-Calmettes, 13274 - Marseille/FR
  • 3 Department Of Medicine, Memorial Sloan Kettering Cancer Center, New York/US
  • 4 Medical Department Iii, SLK-Clinics, MOLIT Institute, 74078 - Heilbronn/DE
  • 5 Aphp Cic And Dermatology Department Inserm 976, University Paris Diderot Hôpital Saint-Louis, 75010 - Paris/FR
  • 6 Medical Oncology, UMC Utrecht Cancer Center, 3584 CX - Utrecht/NL
  • 7 Department Of Surgery, Sanford Health, USD Sanford School of Medicine, Sioux Falls/US
  • 8 Medical Oncology, Earle A. Chiles Research Institute at Providence Cancer Center, 97213 - Portland/US
  • 9 Department Of Oncology, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21231 - Baltimore/US
  • 10 Head And Neck/cutaneous Oncology, Moffitt Cancer Center, Tampa/US
  • 11 Pathology, University of Pittsburgh Medical Center, 15213 - Pittsburgh/US
  • 12 Immuno-oncology Clinical Development, Bristol-Myers Squibb, Princeton/US
  • 13 Global Biometric Sciences, Bristol-Myers Squibb, Princeton/US
  • 14 Department Of Surgery, Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, 21287-8934 - Baltimore/US


Abstract 3044


Immune checkpoint inhibitors used in the neoadjuvant setting may enhance systemic immunity to prevent tumor recurrence, and previous data suggest administration in the preoperative setting is safe. CheckMate 358 explored the safety and feasibility of neoadjuvant nivolumab in patients (pts) with resectable human papillomavirus (HPV)+ or HPV− SCCHN.


This cohort is part of an ongoing global, multicenter study of virus-associated cancers (CheckMate 358; NCT02488759). Pts were PD-L1–unselected with newly diagnosed, previously untreated, resectable, HPV+ or HPV− SCCHN of the oral cavity, pharynx, or larynx with T1 or greater primary lesions and N1 or greater nodal disease. Pts were to receive nivolumab 240 mg on days 1 and 15 and surgery on day 29 ± 7. Tumor assessments by CT scan occurred at screening, presurgery, and during follow-up. Pretreatment tumor biopsies, surgical specimens, and peripheral blood were collected. Primary endpoints were safety (incidence of TRAEs) and delay >4 weeks from planned surgical date due to TRAEs. Investigator-assessed change in tumor dimensions was an exploratory endpoint. Additional assessments include pathologic response, tumor PD-L1 expression, and immune correlates. Preliminary results from a Feb 2017 database lock are reported.


Of 29 pts enrolled, 12 had HPV+ tumors and 17 HPV−. Median (range) follow-up was 22 (2–41) wks (HPV+) and 12 (4–56) wks (HPV−). All pts received both doses of nivolumab. Grade 3–4 TRAEs occurred in 2 (16.7%) pts with HPV+ tumors (lipase increased; glossodynia) and 2 (11.8%) pts with HPV− tumors (lipase increased); no new safety signals were identified. TRAEs did not result in any protocol-defined surgery delays. As of database lock, presurgery tumor reduction per CT scan was observed in 11 of 23 (48%) evaluable pts (5/10 HPV+ and 6/13 HPV−); 3 pts had tumor reduction ≥40% (largest reduction, 75%).


This is the first report of a global trial of neoadjuvant anti–PD-1 therapy in pts with both HPV+ and HPV− SCCHN. Nivolumab was well tolerated, with no surgery delay due to TRAEs. Nivolumab led to tumor reductions within 1 month in nearly half of evaluable pts.

Clinical trial identification


Legal entity responsible for the study

Bristol-Myers Squibb


Bristol-Myers Squibb


R.L. Ferris: Other from Amgen, Astra-Zeneca/MedImmune, Bristol-Myers Squibb, EMD Serono, Lilly, Merck, Pfizer, VentiRx Pharmaceuticals, outside the submitted work. S.S. Baxi: Consulting fees from BMS, outside the submitted work. U.M. Martens: Personal fees from Bristol-Myers Squibb, Roche, EMD Serono, Amgen, outside the submitted work. W.C. Spanos: Personal fees from BMS, Merck, outside the submitted work. R.S. Leidner: Research support from BMS, MedImmune/AstraZeneca. H. Kang: Grants and non-financial support (to institution) from BMS, during the conduct of the study; grants from Merck, Novartis, Plexxikon, Advaxis, Immunogen, VentiRx Pharmaceuticals, AstraZeneca, outside the submitted work (to institution). J. Russell: Consulting for EMD Serono. I. Soumaoro, S. Rao, Z.A. Cao: Employee of Bristol-Myers Squibb. S. Topalian: Grants and non-financial support from BMS; personal fees from Amgen, MedImmune/AstraZeneca, Merck, Pfizer, AbbVie; Personal fees & other from Five Prime Therapeutics, Jounce Therapeutics; Grants, personal fees & other from Potenza Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.